scholarly journals New-Onset Refractory Status Epilepticus: More Investigations, More Questions

2016 ◽  
Vol 8 (2) ◽  
pp. 127-133 ◽  
Author(s):  
Philippe Dillien ◽  
Susana Ferrao Santos ◽  
Vincent van Pesch ◽  
Vanessa Suin ◽  
Sophie Lamoral ◽  
...  

A 27-year-old previously healthy woman was admitted to the hospital with recurrent seizures. Status epilepticus developed that became refractory to third-line therapy with propofol and barbiturates. The patient had a very extensive diagnostic workup including autoimmune, viral and genetic investigations. A tentative immune therapy was proposed with high doses of steroids and plasma exchanges. Our patient had an inherited heterozygous single nucleotide variant in the sequence c.1280A>G [p.Lys427Arg] of the SMC3 gene that was insufficient to explain the seizures. Surprisingly, IgM antibodies against Japanese encephalitis virus were positive on the serum drawn 11 days after symptom onset, as detected by ELISA and the immunofluorescence antibody (IFA) technique. IgG antibodies were also positive using the IFA technique, but not with ELISA. The same investigations as well as the detection of the viral genome by the q-RT-PCR technique were negative on cerebrospinal fluid. Despite the suspicion of a viral infection, we concluded that our patient had a new-onset refractory status epilepticus of cryptogenic origin. Termination of the status epilepticus was obtained after 47 days, with a possible benefit from the introduction of ketamine.

Author(s):  
Furkan M. Yilmaz ◽  
Lauren A. Igneri ◽  
Yasir A. Yilmaz ◽  
Evren Burakgazi-Dalkilic

The purpose of this review is to summarize the recent literature focusing on intravenous (IV) administration of commonly used anesthetics, including midazolam, pentobarbital/ thiopental, propofol, and ketamine in the treatment of status epilepticus (SE). Anesthetics should be reserved as third-line therapy for the treatment of SE when benzodiazepines and other second-line agents fail to terminate the seizure. We have reviewed the literature related to the treatment of status epilepticus, refractory status epilepticus, super-refractory status epilepticus, anesthetics, midazolam, pentobarbital/thiopental, propofol, and ketamine. This paper focuses on the pharmacology, dosages, major side effects, and clinical use of IV anesthetics in the treatment of SE with an emphasis on the developing literature supporting the use of ketamine for this indication. Based on the available literature, we propose recommendations for third-line agent selection in the management of SE.


2021 ◽  
pp. 153575972199832
Author(s):  
Karnig Kazazian ◽  
Marissa Kellogg ◽  
Nora Wong ◽  
Krista Eschbach ◽  
Raquel Farias Moeller ◽  
...  

New-onset refractory status epilepticus (NORSE) is a rare clinical presentation of refractory status epilepticus (RSE) that occurs in people without active epilepsy or preexisting neurologic disorder. Febrile infection-related epilepsy syndrome (FIRES) is a subcategory of NORSE. New-onset refractory status epilepticus/FIRES are becoming increasingly recognized; however, information pertaining to disease course, clinical outcomes, and survivorship remains limited, and mortality and morbidity are variable, but often high. The objective of the NORSE/FIRES Family Registry is to (1) provide an easily accessible and internationally available multilingual registry into which survivors or NORSE/FIRES surrogates or family members of people affected by NORSE/FIRES or their physicians can enter data in a systematic and rigorous research study from anywhere in the world where internet is available; and (2) to examine past medical history, outcomes, and quality of life for people affected by NORSE/FIRES.


2021 ◽  
Vol 15 ◽  
pp. 100431
Author(s):  
Jonathan P. Donnelly ◽  
Nidhi Kasatwar ◽  
Shaheryar Hafeez ◽  
Ali Seifi ◽  
Andrea Gilbert ◽  
...  

Seizure ◽  
2020 ◽  
Vol 75 ◽  
pp. 174-184 ◽  
Author(s):  
Sidra Aurangzeb ◽  
Lara Prisco ◽  
Jane Adcock ◽  
Mahiri Speirs ◽  
Simon Raby ◽  
...  

2009 ◽  
Vol 284 (1-2) ◽  
pp. 220 ◽  
Author(s):  
Rahul Rathakrishnan ◽  
Einar P. Wilder-Smith

2021 ◽  
Vol 125 ◽  
pp. 108387
Author(s):  
Aidan Neligan ◽  
Bellami Kerin ◽  
Matthew C Walker ◽  
Sanjeev Rajakulendran

2020 ◽  
Vol 41 (10) ◽  
pp. 3003-3006 ◽  
Author(s):  
Monica Ferlisi ◽  
Elena Greco ◽  
Tiziano Zanoni ◽  
Monica Zamagni ◽  
Marilena Casartelli Liviero ◽  
...  

Neurology ◽  
2019 ◽  
Vol 92 (17) ◽  
pp. 802-810 ◽  
Author(s):  
Teneille E. Gofton ◽  
Nicolas Gaspard ◽  
Sara E. Hocker ◽  
Tobias Loddenkemper ◽  
Lawrence J. Hirsch

New-onset refractory status epilepticus (NORSE) is a clinical presentation, not a specific diagnosis, in a patient without active epilepsy or other preexisting relevant neurologic disorder, with new onset of refractory status epilepticus (RSE) that does not resolve after 2 or more rescue medications, without a clear acute or active structural, toxic, or metabolic cause. Febrile infection-related epilepsy syndrome is a subset of NORSE in which fever began at least 24 hours prior to the RSE. Both terms apply to all age groups. Until recently, NORSE was a poorly recognized entity without a consistent definition or approach to care. We review the current state of knowledge in NORSE and propose a roadmap for future collaborative research. Research investigating NORSE should prioritize the following 4 domains: (1) clinical features, etiology, and pathophysiology; (2) treatment; (3) adult and pediatric evaluation and management approaches; and (4) public advocacy, professional education, and family support. We consider international collaboration and multicenter research crucial in achieving these goals.


Sign in / Sign up

Export Citation Format

Share Document